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Purpose: To investigate the effect of bevacizumab (Avastin; Genentech, San Francis-
co, CA, USA) on vascular endothelial growth factor (VEGF) expression and inflam-
mation in fibrovascular membranes in patients with proliferative diabetic retinopathy 
(PDR). Materials and Methods: Fibrovascular membranes from 19 eyes of 18 pa-
tients with PDR were studied using immunohistochemistry and analyzed in the fol-
lowing 3 groups; group 1: 4 inactive PDR eyes, group 2: 10 active PDR eyes treated 
preoperatively with adjunctive intravitreal bevacizumab, group 3: five active PDR 
eyes not treated preoperatively with bevacizumab. Immunohistochemical staining for 
VEGF, CD31 and CD68 were done. Results: The immunoreactivity to VEGF and 
CD 31-positive blood vessels was significantly higher in membranes from group 3 
than group 1 (p = 0.007 for VEGF, 0.013 for CD 31-positive vessels). Intravitreal bev-
acizumab caused a reduction in VEGF expression and vascular densities in 4 out of 
10 (40%) excised membranes from eyes with PDR. However, six membranes (60%) 
in group 2 still demonstrated relatively strong VEGF expression and high vascular 
density. Infiltration of macrophages was observed in 16 out of the 19 membranes, and 
the density of macrophages was increased in group 2 compared with group 1 (p = 
0.043). Conclusion: Intravitreal bevacizumab injections caused some reduction in 
VEGF expression and vascular densities in a limited number of active PDR patients. 
A single intravitreal bevacizumab injection may not be enough to induce complete 
blockage of VEGF and pathologic neovascularization in active PDR patients. Repeat-
ed injections, panretinal photocoagulation and/or PPV may be necessary following in-
travitreal bevacizumab to reinforce the anti-VEGF effect of the drug.
Key Words:    Intravitreal bevacizumab, proliferative diabetic retinopathy, vascular 
endothelial growth factor 
INTRODUCTION
Proliferative diabetic retinopathy (PDR) is characterized by a pathological growth Eun Jee Chung, et al.
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tween 1 August 2006 and 28 February 2007. The study fol-
lowed the tenets of Declaration of Helsinki and was ap-
proved by the local Institutional Review Board. Signed and 
written informed consent was obtained from each patient. 
The surgically removed fibrovascular membranes were 
classified into those with inactive (group 1) and active neo-
vascularization. Neovascularization was considered to be 
active if the new vessels were perfused and had multi-
branched preretinal capillaries, and considered to be inac-
tive if a previously documented active proliferation had re-
gressed, or if gliotic vessels or fibrosis were prominent. Of 
15 active PDR eyes, 10 eyes had received an intravitreal in-
jection of 1.25 mg bevacizumab one week before planned 
pars plana vitrectomy (PPV) (group 2), and 5 eyes had re-
ceived PPV only (group 3). 
Ophthalmic examinations, including visual acuity and in-
traocular pressure measurement, slit lamp examination, di-
lated fundus examination, fluorescein angiography and col-
or fundus photography, were performed at baseline. The 
patients’ clinical data are summarized in Table 1.
Tissue processing
The surgically excised proliferative fibrovascular mem-
branes were fixated in 10% formalin solution in the operat-
ing room and embedded in paraffin. Sections, 4 μm thick, 
were deparaffinized and prepared for immunohistochemi-
cal study and hematoxylin-eosin (H&E) staining.
Immunohistochemical staining
Immunohistochemical analysis was performed using the in-
direct immunoperoxidase staining technique. Endogenous 
peroxidase was blocked by methanol/hydrogen peroxide. 
The poly-clonal rabbit anti-VEGF antibody (Santa Cruz, 
CA, USA) was diluted (1 : 300) in a 0.05-mol/L concentra-
tion of tris (hydroxymethyl) aminomethane-buffered saline 
(pH 7.5) plus 1% bovine serum albumin and applied for 60 
minutes. After washing, the slides were incubated with bio-
tinylated goat antirabbit IgG for 30 minutes, washed and ex-
posed to avidin-peroxidase complex. Three-amino-9-ethyl-
carbazole (AEC) was used as the chromogen. The slides 
were counter-stained with Mayer hematoxylin. Observa-
tions of the immunostaining were made under a light mi-
croscope. When the specimens were too small to provide 
sufficient sections for all the immunostaining procedures, 
they were discarded from the study. Omission of the prima-
ry antibody in a matched serial epiretinal membrane sec-
tion, which lacks the specific staining of the respective pri-
of new blood vessels that often results in catastrophic loss 
of vision due to vitreous hemorrhage and/or tractional reti-
nal detachment (TRD). 
Vascular endothelial growth factor (VEGF) is an angio-
genic mitogen, and the involvement of VEGF in PDR has 
been suggested by studies that have demonstrated that the 
vitreous humor from eyes with PDR contains a large 
amount of VEGF,1,2 and that VEGF is expressed in fibro-
vascular tissues obtained from PDR patients.3-5 The discov-
ery and cloning of VEGF in 1989 and subsequent develop-
ment of antibodies to it allowed for the identification of 
VEGF’s key role in the development of retinal neovascular-
ization in PDR.6,7 In addition to the key role of VEGF in the 
development of PDR, there is evidence that chronic inflam-
mation may also be involved, as several studies have 
shown elevated levels of inflammatory markers in patients 
with diabetic retinopathy.8-10 
Bevacizumab (Avastin, Genentech, San Francisco, CA, 
USA) is a humanized recombinant antibody that binds to 
most isoforms of VEGF.7 Recent reports have shown that 
intravitreal bevacizumab is well-tolerated in the short term 
for treatment of PDR.11-13 Beneficial effects of intravitreal 
bevacizumab as a preoperative adjunct for TRD in PDR 
has been reported.14,15 Previous studies have also demon-
strated that intravitreal injection of bevacizumab in PDR 
patients significantly reduces the level of VEGF in aqueous 
humor.16-18 Although a reduction of the VEGF level in aque-
ous humor and the regression of fibrovascular proliferation 
have been observed after clinical treatment intravitreal bev-
acizumab, the effect of bevacizumab on retinal neovascular 
membranes is unknown.
In this study, we investigated the clinicohistopathology of 
surgically excised fibrovascular membranes from PDR pa-
tients treated with an intravitreal bevacizumab injection pri-
or to surgery. The expression of VEGF was determined by 
immunostaining, and the level of vascularization was eval-
uated by immunodetection of the endothelial marker CD31. 
The inflammatory infiltration was evaluated using an anti-
body against CD68 as a marker for macrophages.
MATERIALS AND METHODS
Patients
Fibrovascular membranes were obtained from 19 eyes of 
18 patients during vitrectomy at Yonsei University Eye & 
Ear, Nose, and Throat Hospital vitreoretinal service, be-VEGF Expression after Intravitreal Bevacizumab 
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Nemenyi-Damico-Wolfe-Dunn test. Statistical analyses 
were performed with the R (2.8.1) statistics program. The 
level of statistical significance was set at p < 0.05, and the 
results are expressed as mean ± standard deviation. 
RESULTS
Histopathological examinations
The specimens from group 1 had sparse vascularized tissue 
with abundant extracellular matrix and fibrosis. The active 
neovascular membranes from group 3 were composed of 
highly vascularized fibrovascular tissue, and the vessels 
were surrounded by a loosely coherent extracellular matrix. 
Four out of 10 specimens from group 2 demonstrated re-
gressed vascular channels, with the remaining six speci-
mens showing active PDR characteristics including highly 
vascularized tissue. The histopathological findings correlat-
ed well with the clinical findings in the four eyes with re-
gressed active PDR, with the membranes composed of 
large caliber vessels and fibroglial tissue (Fig. 1).
Immunohistochemistry
The results of immunohistochemical staining are summa-
rized in Table 2. Immunoreactivity to VEGF was detected 
in the endothelial cells of newly formed vessels in the ex-
cised fibrovascular membranes. The immunoreactivity to 
VEGF was 0.5 ± 0.6 in group 1, 2.0 ± 0.9 in group 2 and 2.6 
± 0.6 in group 3 (Fig. 2). The numbers of CD31-positive 
blood vessels were 1.3 ± 2.5 in group 1, 11.6 ± 8.4 in group 2 
and 17.0 ± 10.4 in group 3 (Fig. 3). The immunoreactivity 
to VEGF and the number of CD31-positive blood vessels 
were significantly higher in membranes from group 3 than 
mary antibody, was used as a negative control.
To study endothelial cell and macrophage distribution, 
monoclonal mouse antibodies against CD31 (1 : 100 dilu-
tion; DakoCytomation, Glostrup, Denmark) and CD68 (1 : 
100 dilution; DakoCytomation, Glostrup, Denmark) were 
used to visualize endothelial cells and macrophages, re-
spectively. Counting of CD31 and 68-positive cells and im-
munoreactivity scoring for VEGF were performed by an 
independent observer (JSK) with no knowledge of the pa-
tients’ clinical information.
The immunoreactivity for VEGF was analyzed and semi-
quantitatively scored on a scale from 0 to 3 depending on 
the staining intensity as follows: 0) no detectable staining in 
the specimen; 1) weak; 2) intermediate; 3) strong.
Immunohistochemical staining of vascular densities for 
CD31, which stains vascular endothelial cells, was con-
ducted.19 The number of CD31-positive vessels were count-
ed at ×400 power magnification covering the whole stromal 
area of the membrane and expressed as the average of the 
three highest readings. Any endothelial cells or clusters that 
were stained brown and clearly separated from the connec-
tive tissue elements were considered as single countable 
microvessels. The number of CD68-positive cells was 
counted at ×400 power magnification covering the whole 
stromal area of the membrane and expressed as the average 
of the three highest readings. 
Statistical analysis
The baseline demographic and clinical parameters were 
compared between treatment groups using a Kruskal-Wallis 
variance analysis for continuous variables and chi-squared 
tests for categorical variables. Comparisons of study end-
points using comparisons between groups employed the 
Table 1. Patient Demographic Data
Characteristics Group 1 (n = 4) Group 2 (n = 9) Group 3 (n = 5) p value
Age (yrs)   48.3 ± 11.9 54.6 ± 9.9   54.8 ± 10.5  0.715*
Female gender, no. (%)   1 (25) 7 (77) 4 (80) 0.109
†
Duration of diabetes (yrs) 16.5 ± 2.4 11.5 ± 8.1 11.2 ± 5.9  0.338*
DM nephropathy, no. (%) 0 (0) 4 (44) 2 (40) 0.310
†
Hemoglobin A1c (%)   6.7 ± 0.9   8.0 ± 1.7   8.8 ± 2.7  0.205*
PRP no. (%)     4 (100)  7 (77) 2 (40) 0.303
†
Vitreous hemorrhage no. (%)   2 (50) 7 (77) 4 (80) 0.480
†
TRD no. (%)   1 (25) 4 (44) 3 (60) 0.561
†
n, number of patients; PDR, proliferative diabetic retinopathy; DM, diabetes mellitus; PRP, panretinal photocoagulation; TRD, tractional 
retinal detachment. 
*Kruskal-Wallis variance analysis.
†Chi-square test.Eun Jee Chung, et al.
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expression, vascular density and macrophage infiltration 
were not significantly different between groups 2 and 3. 
There were significant correlations between immunoreac-
tivity to VEGF and the number of CD31-positive vessels (r 
= 0.824, p < 0.001, Spearman correlation) and the number 
of CD68-positive macrophages (r = 0.485, p = 0.035). 
DISCUSSION
We observed that immunoreactivity to VEGF was significant-
ly stronger in membranes from active PDR compared to those 
from inactive PDR. The number of CD31-expressing blood 
vessels was also significantly higher in the active group. The 
those from group 1 (p = 0.007 for VEGF, 0.013 for CD 
31-positive vessels, Nemenyi-Damico-Wolfe-Dunn test). 
Intravitreal bevacizumab caused a reduction in VEGF ex-
pression and vascular densities in four out of 10 eyes (40%) 
in group 2, and the histopathological findings in the excised 
membranes showed regressed PDR (Figs. 1B, 2B, and 3B). 
However, six eyes (60%) in group 2 exhibited strong 
VEGF expression and high vascular densities even after the 
intravitreal bevacizumab injections (Figs. 1C, 2C, and 3C). 
Infiltration of CD68-positive macrophages was observed in 
16 out of 19 membranes. The number of CD68-positive 
macrophages was 1.5 ± 2.4 in group 1, 18.5 ± 8.4 in group 
2 and 8.8 ± 5.7 in group 3 (Fig. 4). The number was signifi-
cantly larger in group 2 than in group 1 (p = 0.043). VEGF 
A B C D
Fig. 1. Representative fundus photographs and histopathologic findings. (A) Group 1. A fibrotic fibrovascular membrane can be seen in this fundus photo. This 
section of excised tissue shows sparsely vascularized fibrovascular tissue in H&E staining. (B) Group 2 with regression of active PDR. Regressed NVD, large 
caliber vessels and gliosis are evident. Sparsely vascularized tissue is present in H&E staining. (C) Group 2 with active PDR. (D) Group 3. Proliferative fibrovascu-
lar membranes and preretinal hemorrhage can be seen. H&E staining shows highly vascularized tissue (original magnification × 400). PDR, proliferative diabetic 
retinopathy; NVD, neovascular at the disc.
A B C D
Fig. 2. Immunohistochemistry for vascular endothelial growth factor (VEGF) expression. (A) Group 1. Weak immunoreactivity to VEGF is observed in fibrovascular 
tissue. (B) Group 2 with regression of active proliferative diabetic retinopathy (PDR). The immunoreactivity to VEGF shows intermediate staining in vascular en-
dothelial cells surrounding the vascular lumen. (C) Group 2 with active PDR (D) Group 3. Strong immunoreactivity to VEGF is shown (original magnification × 400). 
Table 2. The Results of Immunohistochemical Staining
Primary antibody Group 1 (n = 4) Group 2 (n = 10) Group 3 (n = 5)
VEGF (SD) 0.5 (0.6)   2.0 (0.9)   2.6 (0.6)* 
CD31-positve vessels (SD) 1.3 (2.5) 11.6 (8.4)    17.0 (10.4)*
CD68-positive cells (SD) 1.5 (2.4)    18.5 (8.4)* 8.8 (5.7)
n, number of eyes; VEGF, vascular endothelial growth factor; SD, standard deviation.
*indicates p < 0.05 compared to the group 1, Nemenyi-Damico-Wolfe-Dunn test.VEGF Expression after Intravitreal Bevacizumab 
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Based on the observations of the current study and a recent 
report by Kubota, et al.20 vascular endothelial cells would 
not disappear in all patients in a short period after the injec-
tion of bevacizumab. On the contrary, they showed signifi-
cant decreases in VEGF expression in fibrovascular mem-
branes after a bevacizumab injection, which is contradictory 
to our results.20 The tissue-expressed VEGF level may vary 
greatly among PDR patients, and a single bevacizumab in-
jection would result in a different level of VEGF expression. 
Further studies of larger groups are warranted to verify these 
findings. Some reports also demonstrated a clinically favor-
able outcome associated with intravitreal bevacizumab in 
active PDR patients. However, even in those reports, partial 
regression of the active PDR was observed in 34 to 41% of 
the patients, indicating that a single bevacizumab injection 
may not be enough to cause complete regression of active 
PDR.13,21
VEGF is also a chemotactic factor for inflammatory 
cells, activating monocytes and macrophages, and induces 
the expression of ICAM-1 and E-selectin on vascular endo-
thelial cells to facilitate adhesion and migration of inflam-
matory cells.22-27 Since angiogenesis and inflammation are 
closely related, we hypothesized that VEGF inhibition by 
bevacizumab may influence new vessel formation as well 
as inflammatory activity in PDR membranes. In specimens 
treated with bevacizumab, the number of CD68-positive 
macrophages was comparable to that of active PDR cases 
without preoperative adjunctive therapy, and significantly 
results are consistent with previous reports that have demon-
strated increased VEGF levels in both vitreous humor and se-
rum, and highly expressed VEGF in the endothelial cells of fi-
brovascular membranes from eyes of PDR patients.1-5 There 
was a significant correlation between the immunoreactivity to 
VEGF and the number of CD31-positive vessels, supporting 
the theory that VEGF may play an important role in the pro-
gression of neovascularization in PDR.1,2 
In 40% of the eyes that were treated with intravitreal bev-
acizumab injection and PPV, significant decreases in VEGF 
expression and vascular densities were observed. In those 
eyes, the decrease in immunoreactivity to VEGF and vas-
cular densities correlated with the regression of NVD and 
large caliber vessels and the presence of fibroglial tissue 
comprising the NVE. However, relatively strong expres-
sion of VEGF and high vascular densities were observed in 
the other 60% of membranes, even after preoperative ad-
junct bevacizumab injection. In contrast with our observa-
tions, previous studies have shown a significant reduction 
in VEGF level in both the vitreous and aqueous humor in 
active PDR patients after a single intravitreal bevacizumab 
injection.16-18 However, these studies reported levels of free 
VEGF in the vitreous or aqueous humor, unlike the tissue-
expressed level as measured in the current study. Kubota, et 
al.19,20 also demonstrated that vascular endothelial cells 
were still present in the fibrovascular membranes from 
PDR patients and trabecular meshwork of neovascular 
glaucoma even after the intravitreal bevacizumab injection. 
A B C D
Fig. 3. Immunohistochemistry for CD31. (A) Group 1. CD31-positive blood vessels are barely visible in fibrovascular tissue. (B) Group 2 with regression of active 
PDR. Vascular lumen with CD31-positive endothelial cells is visible. (C) Group 2 with active PDR. (D) Group 3. Highly vascularized tissue with the vascular lumen 
surrounded by CD31-positive cells (original magnification × 400). 
A B C
Fig. 4. Immunohistochemistry for CD68. (A) Group 1. CD68-positive cells are barely visible in fibrovascular tissue. (B) Group 2. A significant increase in CD68-
positive cells can be seen when compared with (A). (C) Group 3. Moderate increase in CD68-positive cells can be seen (original magnification × 400).Eun Jee Chung, et al.
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